- Meeting abstract
- Open Access
The sorting protein GASP-1 regulates the constitutive signaling capacity of the virally encoded chemokine receptor US28
© Tschische et al; licensee BioMed Central Ltd. 2009
- Published: 12 November 2009
- Luciferase Reporter
- Chemokine Receptor
- Element Binding Protein
- Inositol Phosphate
- Luciferase Reporter Gene
Human cytomegalovirus (HCMV) is a widespread pathogen that has been shown to be present in various malignancies and it is also thought to be linked to vascular diseases. HCMV encodes the seven transmembrane (7 TM)/G protein-coupled receptor (GPCR) US28, which constitutively activates the Gαq/phospholipase C (PLC) pathway and downstream transcription factors such as the nuclear factor-κB (NF-κB) or the cyclic AMP responsive element binding protein (CREB). In this study we set out to elucidate the role of the GPCR-associated sorting protein-1 (GASP-1) in the regulation of the constitutive signaling capacity of US28.
To elucidate the role of GASP-1 in the regulation of the constitutive signaling capacity of US28 we disrupted the US28/GASP-1 interaction by either overexpression of dominant negative cGASP-1 or shRNA knock-down of endogenous GASP-1. To monitor the US28-mediated signaling we conducted inositol phosphate (IP) accumulation assays as well as luciferase reporter gene assays to check the activation of the transcription factors NF-κB and CREB.
We find that GASP-1 is indeed able to modulate the signaling activity of US28. Disruption of the GASP-1/US28 interaction by either i) overexpression of dominant negative cGASP-1 or by ii) shRNA knock-down of endogenous GASP-1 alters the US28-mediated Gαq/PLC/IP accumulation as well as the activation of the transcription factors NF-κB and CREB.
By identifying the sorting protein GASP-1 as a key regulator of the constitutive signaling activity of US28, we may be one step closer to gaining a better understanding of this viral receptor and its significance in the pathogenesis implicated by HCMV.
This article is published under license to BioMed Central Ltd.